Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate of 18.62%
Flat results in Dec 25
With ROE of 0, it has a Very Expensive valuation with a 1.4 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0% of the company
Stock DNA
Healthcare Services
INR 973 Cr (Micro Cap)
427.00
21
0.00%
0.01
0.01%
1.51
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Jul-23-2012
Risk Adjusted Returns v/s 
Returns Beta
News

Sastasundar Ventures Ltd Technical Momentum Shifts Amid Mixed Market Signals
Sastasundar Ventures Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly indicators, the overall technical landscape suggests caution for investors as the stock faces downward pressure, reflected in a 2.47% decline on 20 May 2026 to close at ₹286.00.
Read More
Sastasundar Ventures Ltd is Rated Strong Sell
Sastasundar Ventures Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Sastasundar Ventures Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Sastasundar Ventures Ltd, a micro-cap player in the healthcare services sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent upgrade in its MarketsMOJO grade from Sell to Strong Sell, the stock’s price action and technical indicators reveal a complex picture of mixed signals that investors should carefully analyse.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13-Jun-2026 | Source : BSEDisclosure under Listing Regulations - Submission of Audio recording of the Group Conference call for Q4 FY26
Board Meeting Outcome for Intimation Of The Outcome Of The Meeting Of The Board Of Directors Of The Company Held On June 10 2026 Under Regulation 30 Of The SEBI (LODR) Reg 2015
10-Jun-2026 | Source : BSEPlease find the disclosure attached herewith.
Announcement under Regulation 30 (LODR)-Investor Presentation
10-Jun-2026 | Source : BSEPlease find attached the Investor Presentation.
Corporate Actions 
No Upcoming Board Meetings
Health X Platform Ltd has declared 10% dividend, ex-date: 23 Jul 12
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.0%)
Held by 6 FIIs (2.17%)
Banwari Lal Mittal (33.91%)
Lekh Raj Juneja (1.89%)
12.25%
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
YoY Growth in quarter ended Mar 2026 is 30.77% vs -6.79% in Mar 2025
YoY Growth in quarter ended Mar 2026 is -181.71% vs -16.85% in Mar 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 10.28% vs -21.70% in Sep 2024
Growth in half year ended Sep 2025 is 114.40% vs -1,043.91% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 14.59% vs -22.82% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 111.78% vs -1,286.77% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 18.75% vs -19.25% in Mar 2025
YoY Growth in year ended Mar 2026 is 101.29% vs -1,126.69% in Mar 2025